TGF-.beta.1 to improve neural outcome
US6204240A · kind A · utility
2Cited by
5References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 2, 1994 |
| Grant date | Mar 20, 2001 |
| Priority date | — |
| Expiry date | May 2, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/1841
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods of treating injuries to or diseases of the central nervous system which methods involve increasing the active concentration(s) of transforming growth factor beta 1 (TGF-.beta.1) and/or analogues thereof in the central nervous system of the patient. The present invention also provides pharmaceutical compositions comprising TGF-.beta.1 and/or analogues thereof for administration to a patient prior to, simultaneous with, or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.